Page 157 - 2019_05-HaematologicaMondo-web

Mogamulizumab vs. investigator's choice in ATL
26. Hisada M, Stuver SO, Okayama A, Li HC, et al. Persistent paradox of natural history of human T lymphotropic virus type I: par- allel analyses of Japanese and Jamaican car- riers. J Infect Dis. 2004;190(9):1605-1609.
27. Bazarbachi A, Suarez F, Fields P, et al. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118(7):1736-1745.
28. Tobinai K, Uike N, Saburi Y, et al; Cladribine/ATL Study Group, Japan. Phase II study of cladribine (2-chlorodeoxyadeno- sine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol. 2003;77(5):512-517.
29. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lym- phoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy. Br J Cancer. 1994;70(4):771-774.
30. Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggres- sive adult T-cell leukemia/lymphoma. Cancer Sci. 2015;106(9):1219-1223.
31. Ishida T, Fujiwara H, Nosako K, et al.
Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086-4093.
32. Sharma K, Janik JE, O’Mahoney D, et al. Phase II study of alemtuzumab (CAM- PATH-1) in patients with HTLV-1-associat- ed adult T-cell leukemia/lymphoma. Clin Cancer Res. 2017;23(1):35-42.
33. Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrex- ate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018; 131(4):397-407.
34. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-1189.
35. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196,
36. O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or
refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN- 19) Study. J Clin Oncol. 2015;33(23):2492- 2499.
37. Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged sta- ble disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2017;10(1):154.
38. Sekine M, Kubuki Y, Kameda T, et al. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017;98(5):501-507.
39. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in pre- viously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192-1204.
40. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, fol- licular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9);1902- 1909.
haematologica | 2019; 104(5)
1003